Circulating extracellular vesicles as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis: an exploratory pilot study. — CFSMEATLAS
Circulating extracellular vesicles as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis: an exploratory pilot study.
Castro-Marrero, Jesús, Serrano-Pertierra, Esther, Oliveira-Rodríguez, Myriam et al. · Journal of extracellular vesicles · 2018 · DOI
Quick Summary
This small pilot study looked at tiny particles called extracellular vesicles (EVs) in the blood of ME/CFS patients compared to healthy people. The researchers found that ME/CFS patients had higher amounts of these particles, and the particles were smaller than in healthy controls. This suggests that blood tests measuring these particles might one day help doctors identify ME/CFS.
Why It Matters
ME/CFS currently has no established diagnostic biomarkers or FDA-approved treatments, making the search for objective tests critical for patient care. If validated in larger studies, EV measurements could provide a blood-based diagnostic tool and potentially reveal new therapeutic targets for this debilitating condition.
Observed Findings
ME/CFS patients had significantly higher amounts of EV-enriched fraction compared to healthy controls (p=0.007)
Extracellular vesicles were significantly smaller in ME/CFS patients than in healthy controls (p=0.014)
EVs were successfully detected in blood samples using CD9 and CD63 biomarkers via lateral flow immunoassay
Protein cargo and size distribution of EVs were measurable using nanoparticle tracking analysis and Western blot
Inferred Conclusions
Circulating extracellular vesicles show quantitative and qualitative differences between ME/CFS patients and healthy controls, suggesting potential utility as biomarkers
EV analysis may open new avenues for understanding cell-to-cell communication dysfunction in ME/CFS pathophysiology
Further research on EV biology in ME/CFS could identify novel diagnostic and therapeutic targets
Remaining Questions
Can EV measurements reliably distinguish ME/CFS from other conditions causing similar symptoms (specificity and sensitivity validation)?
Do EV abnormalities correlate with disease severity, symptom burden, or functional impairment in ME/CFS patients?
What specific proteins are enriched in ME/CFS-derived EVs and what is their biological function in disease pathogenesis?
What This Study Does Not Prove
This small pilot study does not establish that EV abnormalities cause ME/CFS or prove these particles can reliably diagnose the condition in clinical practice. The findings are preliminary and require independent replication in larger, diverse populations before any clinical application. Correlation between EV changes and disease severity or symptoms was not assessed.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only